Literature DB >> 24989062

Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer.

James E Thompson1,2,3, Andrew Hayen4, Adam Landau5, Anne-Maree Haynes2, Arveen Kalapara5, Joseph Ischia5, Jayne Matthews1, Mark Frydenberg5, Phillip D Stricker1,2,3.   

Abstract

OBJECTIVE: To assess, in men undergoing active surveillance (AS) for low-risk prostate cancer, whether saturation or transperineal biopsy altered oncological outcomes, compared with standard transrectal biopsy. PATIENTS AND METHODS: Retrospective analysis of prospectively collected data from two cohorts with localised prostate cancer (1998-2012) undergoing AS. Prostate cancer-specific, metastasis-free and treatment-free survival, unfavourable disease and significant cancer at radical prostatectomy (RP) were compared for standard (<12 core, median 10) vs saturation (>12 core, median 16), and transrectal vs transperineal biopsy, using multivariate analysis.
RESULTS: In all, 650 men were included in the analysis with a median (mean) follow-up of 55 (67) months. Prostate cancer-specific, metastasis-free and biochemical recurrence-free survival were 100%, 100% and 99% respectively. Radical treatment-free survival at 5 and 10 years were 57% and 45% respectively (median time to treatment 7.5 years). On Kaplan-Meier analysis, saturation biopsy was associated with increased objective biopsy progression requiring treatment (log-rank P = 0.01). On multivariate Cox proportional hazards analysis, saturation biopsy (hazard ratio 1.68, P < 0.01) but not transperineal approach (P = 0.89) was associated with increased objective biopsy progression requiring treatment. On logistic regression analysis of 179 men who underwent RP for objective progression, transperineal biopsy was associated with lower likelihood of unfavourable RP pathology (odds ratio 0.42, P = 0.03) but saturation biopsy did not alter the likelihood (P = 0.25). Neither transperineal nor saturation biopsy altered the likelihood of significant vs insignificant cancer at RP (P = 0.19 and P = 0.41, respectively).
CONCLUSIONS: AS achieved satisfactory oncological outcomes. Saturation biopsy increased progression to treatment on AS; longer follow-up is needed to determine if this represents beneficial earlier detection of significant disease or over-treatment. Transperineal biopsy reduced the likelihood of unfavourable disease at RP, possibly due to earlier detection of anterior tumours.
© 2014 The Authors. BJU International © 2014 BJU International.

Entities:  

Keywords:  active surveillance; disease management; needle biopsy; predictive value of diagnostic tests; prostate cancer

Mesh:

Year:  2014        PMID: 24989062     DOI: 10.1111/bju.12858

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  14 in total

Review 1.  Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.

Authors:  Jonathan H Wang; Tracy M Downs; E Jason Abel; Kyle A Richards; David F Jarrard
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

2.  Active surveillance of prostate cancer: Current state of practice and utility of multiparametric magnetic resonance imaging.

Authors:  Ridwan Alam; H Ballentine Carter; Jonathan I Epstein; Jeffrey J Tosoian
Journal:  Rev Urol       Date:  2017

3.  Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?

Authors:  Pietro Pepe; Antonio Garufi; Giandomenico Priolo; Michele Pennisi
Journal:  World J Urol       Date:  2015-12-23       Impact factor: 4.226

Review 4.  Active surveillance for low-risk prostate cancer - in pursuit of a standardized protocol.

Authors:  Roman Sosnowski; Hubert Kamecki; Siamak Daneshmand; Jan K Rudzinski; Marc A Bjurlin; Francesco Giganti; Monique J Roobol; Laurence Klotz
Journal:  Cent European J Urol       Date:  2020-06-25

Review 5.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

Review 6.  Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices.

Authors:  Netty Kinsella; Jozien Helleman; Sophie Bruinsma; Sigrid Carlsson; Declan Cahill; Christian Brown; Mieke Van Hemelrijck
Journal:  Transl Androl Urol       Date:  2018-02

7.  Current concepts in multiparametric magnetic resonance imaging for active surveillance of prostate cancer.

Authors:  Alexandre Cavalcante; Públio Cesar C Viana; Giuliano B Guglielmetti; José Pontes Junior; Henrique Nonemacher; Mauricio D Cordeiro; Regis Otaviano F Bezerra; Rafael F Coelho; William Carlos Nahas
Journal:  Clinics (Sao Paulo)       Date:  2018-12-10       Impact factor: 2.365

8.  The clinical utility of transperineal template-guided saturation prostate biopsy for risk stratification after transrectal ultrasound-guided biopsy.

Authors:  Wan Song; Minyong Kang; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Hwang Gyun Jeon
Journal:  Investig Clin Urol       Date:  2019-09-11

9.  Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.

Authors:  Vasilis Stavrinides; Francesco Giganti; Bruce Trock; Shonit Punwani; Clare Allen; Alex Kirkham; Alex Freeman; Aiman Haider; Rhys Ball; Neil McCartan; Hayley Whitaker; Clement Orczyk; Mark Emberton; Caroline M Moore
Journal:  Eur Urol       Date:  2020-04-30       Impact factor: 20.096

Review 10.  Active surveillance for prostate cancer.

Authors:  Daniela K Shill; Monique J Roobol; Behfar Ehdaie; Andrew J Vickers; Sigrid V Carlsson
Journal:  Transl Androl Urol       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.